

Vinculin plays a role in neutrophil stiffening and transit through model capillary segments

Brittany M. Neumann¹, Zachary S. Wilson^{1,2}, Kinga Auguste¹, Yasmin Roye¹, Manisha K. Shah³, Eric M. Darling⁴, Craig T. Lefort¹

1. Division of Surgical Research, Department of Surgery, Rhode Island Hospital, Providence, RI 02903, USA
2. Graduate Program in Pathobiology, Brown University, Providence, RI 02912, USA
3. Center for Biomedical Engineering, Brown University, Providence, RI 02912, USA
4. Department of Pathology and Laboratory Medicine, Department of Orthopaedics, School of Engineering, Brown University, Providence, RI 02912, USA

Corresponding Author:

Craig T. Lefort, PhD

Rhode Island Hospital

593 Eddy Street

Providence, RI 02903

Phone: 401-444-2353

craig_lefort@brown.edu

Keywords: Neutrophils, Cell signaling, Actin cytoskeleton, Deformability, Microfluidics

1 **Abstract**

2 Neutrophils are rapidly mobilized from the circulation to sites of inflammation. The mechanisms
3 of neutrophil trafficking in the lung are distinct from those in the periphery, in part because the
4 pulmonary capillaries are the primary site of neutrophil emigration rather than postcapillary
5 venules. Since the diameter of a neutrophil is greater than the width of most pulmonary capillary
6 segments, they must deform to transit through this capillary network, even at homeostasis.
7 Resistance to deformation is primarily due to cortical actin that is rapidly assembled when a
8 neutrophil is exposed to a priming or activation stimulus, resulting in neutrophil stiffening and
9 subsequent sequestration within the pulmonary capillary network. In the current study, we use a
10 microfluidic assay to characterize neutrophil transit through model capillary-like channels. Using
11 techniques from single-particle tracking, we analyzed the cumulative distribution of neutrophil
12 transit times and resolve population-based effects. We found that vinculin, an actin-binding
13 adaptor protein, plays an essential role in neutrophil stiffening in response to formyl-Met-Leu-
14 Phe (fMLP). Vinculin-deficient neutrophils lack the development of a population with slow
15 transit through narrow channels that was observed in both wild-type murine bone marrow
16 neutrophils and HoxB8-conditional progenitor-derived neutrophils. Atomic force microscopy
17 studies provide further evidence that vinculin is required for neutrophil stiffening. Consistent
18 with these findings, we observed that neutrophil sequestration in the lungs of mice is attenuated
19 in the absence of vinculin. Together, our studies indicate that vinculin mediates actin-dependent
20 neutrophil stiffening that leads to their sequestration in capillaries.

21 **Introduction**

22 Acute respiratory distress syndrome (ARDS) has an in-hospital mortality rate of up to
23 40%, and few effective pharmacological therapies exist [1-3]. Part of the difficulty with ARDS
24 treatment is due to its heterogeneity that arises from a wide range of triggers, its broad clinical
25 definition, and variable outcomes [4]. The pathophysiological hallmarks include severe
26 inflammatory injury to the alveolar-capillary barrier, surfactant depletion, loss of aerated lung
27 tissue, and neutrophil infiltration into the lung [5, 6]. Long-term mortality ranges from 11% to
28 60%, and survivors often have significantly reduced quality of life with sequelae including
29 diffuse pulmonary fibrosis, chronic lung disease, neuropsychiatric impairments, critical illness
30 associated polyneuropathy, myopathy, and neuromyopathy [7, 8].

31 There is abundant evidence for the pathophysiological role of dysregulated neutrophil
32 trafficking and activation in ARDS [9]. Activated neutrophils release granular enzymes, reactive
33 oxygen species (ROS), neutrophil extracellular traps (NETs), and pro-inflammatory cytokines in
34 response to stimuli. In an ideal host response, neutrophils deploy an antimicrobial armament
35 once it reaches the site of infection. However, when this response becomes dysregulated,
36 neutrophils can accumulate in the lungs and indiscriminately release cytotoxic species, leading to
37 acute lung injury (ALI) and potentially ARDS [5, 6].

38 Circulating neutrophils passing through the lung exhibit unique capture and trafficking
39 characteristics due to the geometrical features of the microvasculature [10-12]. Capillaries
40 envelop each alveolus and have diameters of 2-15 μm , which is frequently less than the 8-11 μm
41 diameter of a neutrophil [13-15]. Neutrophils must repeatedly deform to pass through the
42 pulmonary capillaries, slowing their transit relative to red blood cells and resulting in their
43 enrichment within the vascular bed of the lungs [10, 11]. These geometrical characteristics of the
44 lung microvasculature result in altered neutrophil homing mechanisms compared to those in the
45 periphery. In contrast to selectin-mediated neutrophil rolling that occurs in postcapillary venules,
46 the initial capture and enrichment of neutrophils in the pulmonary system is due to these cells'
47 mechanical properties (i.e., stiffness) [10, 16]. Additionally, the prominence and role of $\beta 2$
48 integrins in neutrophil interactions within the lung vary depending on inflammation conditions
49 [12, 17-19].

50 Neutrophil stiffness arises from four cellular components: the plasma membrane, which
51 has a low shear modulus and is elastic but also antagonizes actin-based protrusions [20]; the

52 actin cortex, which provides cortical tension and cellular structure; the cytoplasm, which has
53 viscous resistance; and the nucleus, which is modeled as an immiscible Newtonian liquid drop
54 [13]. Each of these components plays a different role in defining the elastic modulus of the cell.
55 The plasma membrane and the interacting actin cortex are the leading players in neutrophil
56 deformation under the time scales and pressures we are investigating.

57 Upon exposure to stimuli, neutrophils reorganize their actin cytoskeleton and polymerize
58 F-actin [21, 22]. These actin-dependent changes reduce neutrophil deformability, resulting in
59 sequestration and prolonged retention within the pulmonary capillaries [10, 23-26]. Although
60 there is abundant evidence linking cortical actin development to neutrophil stiffness, much
61 remains unknown about the biochemical mechanisms responsible for organizing this actin-
62 dependent phenotype. Vinculin is a non-enzymatic scaffolding protein that binds to the actin
63 cytoskeleton and is involved in its reorganization during dynamic processes such as cell migration
64 [27]. In this study, we describe the role of vinculin in mediating neutrophil stiffening, prolonging
65 their transit through microfluidic constrictions that model the pulmonary capillary unit.

66

67 **Materials and Methods**

68 Antibodies and reagents

69 All antibodies used are against murine antigens. Antibodies: PE-anti-CD117 (clone
70 ACK2; BioLegend), APC-anti-Ly6G (clone 1A8; BioLegend), anti-vinculin (Cell Signaling
71 Technologies), HRP-conjugated-anti-Rabbit IgG (Cell Signaling Technologies). Reagents:
72 Zombie Violet Fixable Viability Kit (BioLegend), recombinant murine SCF (BioLegend),
73 recombinant murine G-CSF (BioLegend), N-Formyl-Met-Leu-Phe (fMLP), BioXtra $\geq 99.0\%$
74 (Millipore Sigma), 4-Hydroxytamoxifen (Tocris), carboxyfluorescein succinimidyl ester (CFSE)
75 (BioLegend), SYLGARD 184 Silicone Elastomer Kit, polydimethylsiloxane (PDMS) (Dow
76 Corning), pHrodo Green *S. aureus* BioparticlesTM Conjugate for Phagocytosis (Invitrogen),
77 Gibco Opti-MEM reduced serum media (ThermoFisher Scientific), Fetal Bovine Serum (FBS)
78 — heat inactivated (GeminiBio), 2-mercaptoethanol (Millipore Sigma), penicillin-streptomycin
79 (ThermoFisher Scientific), MEM non-essential amino acids (NEAA) (ThermoFisher Scientific),
80 phosphate-buffered saline (PBS) (ThermoFisher Scientific), Hanks' Balanced Salt Solution
81 containing $\text{Ca}^{2+}/\text{Mg}^{2+}$ (HBSS⁺⁺) (ThermoFisher Scientific), Pluronic F-127 (Millipore Sigma),
82 bovine serum albumin (BSA) lyophilized powder $\geq 96.0\%$ (Millipore Sigma), DNAaseI (Zymo
83 Research), trichloro(1H, 1H, 2H, 2H-perfluorooctyl)silane (Millipore Sigma), blasticidin
84 (Tocris), puromycin (Tocris).

85

86 HoxB8-conditional murine neutrophil progenitors

87 In brief, murine hematopoietic progenitors were isolated from bone marrow with the
88 EasySep Mouse HSPC Enrichment Kit (StemCell Technologies) and transduced with a
89 tamoxifen-inducible expression vector *HoxB8*. The basal media conditions used for cell culture
90 were as follows: Opti-MEM, 10% FBS, NEAA, pen/strep, and 30 μM 2-mercaptoethanol. To
91 maintain cells in the progenitor state, cells were cultured in the presence of 100 nM 4-
92 hydroxytamoxifen (4-OHT), 50 ng/mL recombinant murine stem cell factor (mSCF), and 1
93 $\mu\text{g}/\text{mL}$ puromycin for selection of the transduced cells. The surviving cells made up our WT
94 progenitor cell lines [28-30]. In some cases, 2% conditioned media from CHO cells producing
95 SCF was used in place of mSCF (a gift from Dr. Patrice Dubreuil).

96 Differentiation of progenitors into neutrophils was performed by washing the cells
97 extensively with PBS and resuspending them in basal media containing 20 ng/mL mSCF and 20

98 ng/mL recombinant murine granulocyte colony-stimulating factor (mG-CSF) for two days. On
99 day two, cells were washed and resuspended in basal media with 20 ng/mL mG-CSF for three
100 days. Successfully differentiated neutrophils exhibit multi-lobed nuclei, expression of Ly6G, and
101 loss of expression of CD117 (cKit) [28-30].

102

103 Gene disruption

104 To generate a vinculin knockout (*Vcl*^{-/-}) progenitor cell line, HoxB8-conditional
105 progenitors were transduced with a lentiviral vector that expressed Cas9 and single-guide RNA
106 (sgRNA) targeting the *Vcl* gene. We modified the pLentiCRISPR v2 vector (gift from Feng
107 Zhang – Addgene plasmid #52961) to confer blasticidin resistance and the following sgRNA
108 target sequences: CCGGCGCGCTCACCCGGACG [29]. Empty vector expression of Cas9
109 without targeting sgRNA was used as wild-type (WT) control. *Vcl*^{-/-} was selected via blasticidin
110 selection at 5 µg/mL concentration. Gene disruption was confirmed via western blot [29].

111

112 Atomic Force Microscopy (AFM)

113 AFM was performed using similar methods to those previously published [31, 32].
114 Coverslips (#1.5) were plasma cleaned before adding neutrophils. *In vitro*-derived murine
115 neutrophils were differentiated and used on day 4. Neutrophils were stimulated for 15 minutes in
116 HBSS⁺⁺ with either vehicle control or 1 µM fMLP at 37°C.

117 Cantilevers were purchased from Novascan Technologies with 5 µm borosilicate beads (k
118 ~ 0.03 N/m). Cantilever spring constants were determined by the power spectral density of
119 thermal noise fluctuations. Cantilevers were used to probe neutrophils using elastic indentation
120 tests with an approach velocity of 10 µm/s. A 0.6 nN trigger force was used to limit indentations
121 to less than 10% strain based on the cell's height. All tests were done at room temperature. A
122 modified Hertz model (Equation 1) was used to determine the elastic modulus:

$$123 \quad F(\delta) = \frac{4R^{1/2}E_{\text{elastic}}}{3(1-\nu^2)}\delta^{3/2}C \quad (1)$$

124 **F** is the applied force, **δ** is the indentation, **R** is the relative radius of the spherical probe
125 (Equation 2), **ν** is the Poisson's ratio (assumed to be 0.5 for incompressible materials), **C** is a
126 thin-layer correction factor relating indentation depth, tip radius, and sample thickness [33]. **R**

127 accounts for the curvature of the probe tip and cell at the point of contact based on **h** (the height
128 of the cell) [31]:

$$129 \quad R = \left(\frac{1}{R_{\text{probe}}} + \frac{1}{h/2} \right)^{-1} \quad (2)$$

130 The cell height was significantly decreased after fMLP treatment, but no difference was found
131 between WT and *Vcl*^{-/-} neutrophils.

132

133 Neutrophil sequestration in mice

134 The Lifespan Animal Welfare Committee approved all animal studies. Mice were housed
135 in a specific pathogen-free facility at Rhode Island Hospital. Mice harboring floxed *Vcl* alleles
136 (*Vcl*^{f/f}) were kindly provided by Dr. Robert Ross (UC-San Diego) as previously described [34].
137 *Vcl*^{f/f} mice were crossed with Mx1-Cre (*Mx1*^{cre}) mice (The Jackson Laboratory) in which Cre
138 recombinase expression is controlled by the Mx1 promoter and can be induced by interferon
139 production after administration of synthetic double-stranded RNA (PolyI: C) [35]. To generate
140 mixed chimeric mice harboring multiple neutrophil genotypes, 8- to 12-week-old C57BL/6 mice
141 (The Jackson Laboratory) were lethally irradiated (10 Gy, single dose) and then reconstituted by
142 intravenous injection of bone marrow cells from a *Vcl*^{f/f}*Mx1*^{cre}GFP⁺ mouse expressing enhanced
143 green fluorescent protein (EGFP) under the ubiquitin C promoter (The Jackson Laboratory) and
144 a *Vcl*^{f/f} (GFP⁻) control mouse at 1:1 ratio. Disrupting the *Vcl* gene encoding vinculin was induced
145 by intraperitoneal injection of 250 µg of polyinosinic-polycytidylic acid (InvivoGen), three
146 doses, each two days apart, starting four weeks after irradiation, inducing near-complete loss of
147 the respective protein in neutrophils [29]. Murine mixed chimeras were administered 5 µg/kg
148 GM-CSF intravenously while anesthetized using a cocktail of ketamine (125 mg/kg) and
149 xylazine (12.5 mg/kg). Peripheral blood was sampled via saphenous venipuncture. The inferior
150 vena cava was excised to allow pulmonary circulation to flow out from the heart, and the lungs
151 were perfused of unbound cells with 5 mL of HBSS⁺⁺ via the right ventricle. Lungs were
152 harvested and briefly rinsed in HBSS⁺⁺ before digestion according to the Lung Digestion Kit
153 manufacturer's protocol (Miltenyi). We analyzed the frequency of WT (GFP⁻) and *Vcl*^{-/-} (GFP⁺)
154 neutrophils in blood and lung tissue samples using flow cytometry.

155

156 Phagocytosis assay

157 Differentiated (day five) neutrophils were washed 3X in PBS. 2×10^6 neutrophils were
158 resuspended in a 100 μ L mixture of pHrodo Green *S. aureus* bioparticles (0.3 mg/mL), FBS (10%
159 v/v) and HBSS⁺⁺. The samples were incubated for 0 or 90 min at 37°C. To quench neutrophil
160 phagocytosis, 1 mL of ice-cold PEB (PBS, 1 mM EDTA, 1% BSA) was added to the samples
161 and placed on ice. To confirm actin-dependent bioparticle internalization, samples were exposed
162 to 10 μ g/mL cytochalasin D. After phagocytosis, samples were stained with Zombie Violet and
163 APC-Ly6G and then analyzed by flow cytometry using a MACSQuant 10 (Miltenyi). Data were
164 analyzed to quantify the fraction of Ly6G^{high} neutrophils with a positive pHrodo FITC signal.
165 This experiment was performed with the conditions in duplicate and parallel and repeated across
166 three independent experiments.

167

168 Microfluidic assay

169 *Microfluidic device construction*

170 AutoCAD was used to design the microfluidic constriction platforms. Photolithography
171 was performed by Front Range Photomask. The silicon master (SU-8) was then manufactured at
172 the Microfabrication Core Facility at Harvard University. Silanization of the silicon wafer was
173 performed to passivate the surface and allow for easy release of the PDMS. To silanize the
174 master, 20 μ L of the silanizing agent — trichloro(1H, 1H, 2H, 2H-perfluorooctyl)silane — was
175 placed next to the silicon wafer within a vacuum desiccator for 30 min. Vacuum was applied for
176 30 min to form the silane monolayer on the master surface. Finally, the silicon wafer was placed
177 on a hotplate at 150°C for 10 min to evaporate the excess silane.

178 To prepare the PDMS, a 10:1 ratio of the elastomer to curing agent was mixed and then
179 subjected to degas for an hour. The PDMS was then poured over the silicon master and then
180 baked overnight at 60°C on a hotplate to harden the polymer. The PDMS stamps with the
181 molded microfluidic design imprinted on them were cut out and holes were punched using a
182 blunt 18G needle for inlet and outlet tubing. The surface of the PDMS was cleaned with Scotch
183 tape. Glass coverslips are soaked in concentrated sulfuric acid overnight, rinsed with copious
184 amounts of water (18 Ω), and then rinsed with 70% ethanol solution and dried. The PDMS stamp
185 (design side up) and the glass coverslip were exposed to the corona discharge generated by a
186 Tesla coil (Model BD-20, Electro-Technic Products, Inc.) for two minutes. The PDMS stamp

187 and the glass coverslip were then sandwiched together (design facing the glass) to form the
188 whole microfluidic device. The microfluidic platforms were left overnight to ensure strong
189 adherence.

190

191 *Neutrophil transit through constrictions*

192 A microfluidic device with constrictions 5 μm across and 8 μm high was designed for this
193 assay, adapted from a design kindly provided by Dr. Amy Rowat. The transit of neutrophils
194 through the constrictions was imaged using fluorescence microscopy. For schematic A of Figure
195 1, hydrostatic pressure was used to drive the neutrophils through the device. A buffer column set
196 at 10 cmH_2O was used and the fluid velocity at the constrictions was measured to be 0.026
197 mm/s . Images were acquired at a frame rate of 10 frames/s for 20 min. When experiments were
198 performed using the microfluidic device shown in schematic B of Figure 1, a syringe pump was
199 used due to the high fluid resistance resulting from the mixing channel. The flow rate set on the
200 syringe pump (Braintree Scientific) was 500 nl/min for two syringes for a total of 1 $\mu\text{L/min}$
201 throughout the device. This resulted in an average fluid velocity of 0.116 mm/s , which is similar
202 to the reported values for fluid velocity in the pulmonary capillaries, ranging from 0.11 mm/s –
203 0.28 mm/s [15, 36, 37]. Images were acquired at a frame rate of 19 frames/s for 20 min for these
204 experiments. These data were exported as TIFF files to ImageJ, where the tracks were built with
205 the plugin Trackmate [38, 39].

206

207 *Data analysis - constriction microfluidics*

208 The Fiji plugin TrackMate [38] was used for analysis to identify and locate the
209 neutrophils and link them into tracks over time. Each track was visually inspected to confirm the
210 linkages. Tracks were then transferred into Mathematica for final filtering. This filtering is based
211 on a series of gates that the neutrophil must pass to be counted. The first gate is 50 pixels from
212 the array entrance, the second gate is 20 pixels before the center of the constriction, and the final
213 gate is 50 pixels from the end of the array.

214 Additionally, data were filtered according to cell diameter. The estimated diameters
215 calculated by TrackMate are based on finding the edge of the cell by contrast [38]. We select a
216 wide range of 4 to 12 microns, which results in ± 4 microns around the estimated median.
217 There are 0.437 microns/pixel. Calculating the neutrophil's diameter is susceptible to pixels

218 turning on and off, and we find it is only a rough estimate of the cell's actual size. Flow
219 cytometry, in which we can identify mature neutrophils via labeling, is a more accurate estimate
220 for neutrophil size, as shown in Supplemental Figure 1. The result of the filtering described
221 above leaves us with a series of tracks where we can determine the transit time of each
222 neutrophil as a correlation to the cell stiffness.

223 Neutrophil transit times from three independent experiments were pooled. Using Excel,
224 we randomly selected 185 transit times from the pooled data. We use the following macro:
225 `=INDEX(A1:A530, RANK(B1,B1:B530))`. We also assign a random distribution of
226 real numbers 0 to 1, using the `RAND()` function, to our pooled data set to prevent duplicates.
227 This method ensures that the data is evenly weighted across our comparisons. These data were
228 then exported back into Mathematica, where their cumulative distributions were plotted against
229 time to yield final kinetic curves. The final fits and statistical analysis were performed with
230 Prism.

231

232 *Neutrophil preparation*

233 On the day of the microfluidic experiment, differentiated neutrophils were washed 3X in
234 optimal buffer (PBS, 1 mM EDTA, 2% FBS). Neutrophils were then purified using an EasySep
235 Mouse Neutrophil Enrichment Kit (StemCell Technologies). The cell samples were always kept
236 on ice until used in the microfluidic device. 1×10^6 cells were removed from the purified
237 neutrophil mixture, washed 2X with PBS, and resuspended in 200 μ L of PBS. These cells were
238 stained with CFSE for 15 min, washed 2X with PBS, and counted. They were then resuspended
239 in filtered (0.22 μ m) HBSS⁺⁺, 0.1% Pluronic solution, 1% BSA, and 3 μ g/mL DNAaseI so that
240 the final concentration was equal to 1.0×10^6 cells/mL. In a separate tube, the stimulus mixture
241 was prepared with HBSS⁺⁺, 0.1% Pluronic solution, 1% BSA, 3 μ g/mL DNAaseI and 2 μ M
242 fMLP. The stimulus of the neutrophils is achieved within the microfluidic device by having two
243 inlets — one for the neutrophils and the other for the stimulus. The final concentration of the
244 stimulus on-chip was 1 μ M. All solutions were at room temperature except the optimal buffer,
245 which was ice-cold. The neutrophil and stimulus solutions were drawn into 1 mL syringes with
246 26G needles. The syringes were attached to the microfluidic chip with polyethylene (PE 50)
247 tubing.

248

249 *Microscopy*

250 The samples were imaged with a TILL Photonics iMIC microscope (FEI Company) with
251 an Olympus 10X UPlanFI objective, NA 0.30. The camera was an Andor iXon3 EMCCD
252 camera. We capture an image every 0.053 s for 20 min.

253

254 Statistical analyses

255 To determine which model represents the data accurately, the 95% confidence bands
256 were plotted around the fits. Next, the residuals of the fit were inspected to check for a random
257 distribution across the x-axis (all residuals for the fitted curves are in Figure S1). Finally, a
258 calculation was performed of the Extra sum-of-squares F test with the rule for selection of the
259 simpler model unless the P-value is greater than 0.05. To compare the best fits between two
260 different models, an unpaired, parametric t-test was performed and the standard deviation of the
261 residuals ($Sy.x$) was used to estimate goodness-of-fit. Three independent experiments were
262 performed and all experimental conditions were evaluated in parallel within each experiment.
263 For bone marrow neutrophil studies, neutrophils were purified from three different mice.

264 Neutrophil phagocytosis experiments were analyzed using a 2-way ANOVA with a
265 Dunnet multiple comparisons test.

266

267

268 **Results**

269 *Design of a microfluidic cell constriction device*

270 To probe neutrophil transit through constrictions that model the dimensions of pulmonary
271 capillaries, we utilized two different microfluidic devices adapted from Nguyen and Hoelzle [40,
272 41] (Figure 1). The initial design, Figure 1A, has a stimulus inlet, a cell inlet, a filter region, a
273 flow bypass ring, and the single-cell constriction array. The design in Figure 1B has the same
274 features and also includes a long mixing channel to ensure adequate and consistent stimulus
275 exposure for the neutrophils. The filter region prevents debris from the inlets from traveling
276 further into the microfluidic device and also disperses clumps of neutrophils so that only single-
277 cell species traverse through the constriction array. Details about the experiments using each of
278 the device designs are provided below with the support of neutrophil transit data. The narrowest
279 widths in the constriction array are 5 μm and the height across the device is 8 μm .

280 Figure 2A shows an example of a CFSE-stained neutrophil transiting a constriction
281 (Video 1). The constriction array through which the neutrophils pass is imaged for 20 min, and
282 then image sequences are subjected to analysis (Figure 2B, 2C) [39]. The transit times of
283 neutrophils are plotted as cumulative distributions (Figure 3A) and fit to one of two continuous
284 functions. More traditional forms of mathematical description, such as reporting the median or
285 average single-cell transit time do not adequately account for the full range of observed cell
286 transit behavior and therefore result in the loss of the experimental resolution provided by this
287 microfluidic device. The functions are a one-phase exponential rise and a two-phase exponential
288 rise. The mathematical model of the one-phase exponential rise is:

289 Eq 1.
$$Y=Y_0+(Y_{\max}-Y_0)*(1-\exp(-k*x)),$$

290 and a two-phase association,

291 Eq 2.
$$Y=Y_0+\text{SpanFast}*(1-\exp(-k_{\text{Fast}}*x))+\text{SpanSlow}*(1-\exp(-k_{\text{Slow}}*x))$$

292 Eq 3.
$$\text{SpanFast}=(Y_{\max}-Y_0)*\text{PercentageFast}*0.01,$$

293 Eq 4.
$$\text{SpanSlow}=(Y_{\max}-Y_0)*(100-\text{PercentageFast})*0.01,$$

294 Where each of the terms represents the following: Y is cell fraction, Y_0 is the cell fraction at 0s,
295 Y_{\max} is the plateau (maximum cell fraction), k is the rate constant and its reciprocal, $(\frac{1}{k})$, is the

296 average transit time, and x is time (s). We use the Extra sum-of-squares F-test to choose the
297 mathematical model that best describes the response to each condition. By fitting the neutrophil
298 transit time population trends, we can determine if there are multiple neutrophil populations
299 within each condition and their associated mean transit times.

300

301 *Bone marrow neutrophil transit through model capillary segments*

302 We measured the transit times of murine bone marrow neutrophils (BMNs) using the
303 microfluidic platform shown in Figure 1A. Samples were exposed to either control conditions
304 (blue curve) or stimulated with 1 μ M fMLP (red curve). Neutrophils were treated with
305 cytochalasin D (CytoD) in combination with fMLP to demonstrate the dependence of neutrophil
306 stiffening on F-actin polymerization (black curve). CytoD is a membrane-permeable fungal toxin
307 that binds to the barbed end of actin filaments, inhibiting both the association and dissociation of
308 subunits.

309 Neutrophil transit time curves under control and fMLP stimulus conditions exhibit a lag
310 phase, representing 6% and 3% of the neutrophil population, respectively (Figure 3A inset and
311 3B). The lag phase describes the fastest transiting events under each condition and is likely due
312 to the underlying resistance to deformation under the flow and pressure conditions used. This
313 results in neutrophils transiting at the times represented in the lag phase being rare. The linear
314 slopes between these two conditions are not significantly different, with a p-value of 0.14. This
315 suggests that the deformability characteristics of these rare, fast transiting neutrophils under
316 these two conditions are similar. After the lag phase, rates accelerate and the transit time curve is
317 best described with an exponential rise function.

318 For the control condition, the acceleration of the population through the constrictions is
319 fully described by a single-phase exponential rise (Eq. 1, Figure 3A). The average transit time for
320 this one-phase exponential is 1.0 s [95% CI 0.92 – 1.2] (Figure 3C). Thus, the control neutrophils
321 have two populations characterized by a lag phase and an exponential rise. The transit time curve
322 for neutrophils exposed to CytoD and fMLP fits a single exponential phase with an average
323 transit time of 1.5 s [95% CI 1.4 – 1.6] (Figure 3C).

324 For neutrophils stimulated with fMLP, the transit time curve has three phases: a lag and
325 two exponential rise phases that were designated as “slow” and “fast”. The two-phase
326 exponential has 97% [95% CI 97 – 98] of the neutrophil population in the fast phase with an

327 average transit time of 1.3 s [95% CI 1.2 – 1.4] and 2.5% of the population in the slow phase
328 with an average transit time of 36 s [95% CI 20 – 67] (Figure 3B, 3C).

329 Together, our analyses indicate that the transit of BMNs through narrow constrictions can
330 be described by fitting their distribution curves to a continuous function with multiple phases. By
331 quantifying neutrophil transit times under various conditions, we identify three distinct
332 subpopulations of neutrophils. Our data indicates that neutrophils predominantly transit through
333 a model capillary unit with characteristic “fast” kinetics, regardless of the presence of fMLP as
334 an activating stimulus. A minority of neutrophils exhibits transit kinetics characterized by a lag
335 phase that is abolished by disrupting the actin cytoskeleton. Finally, stimulation of neutrophils
336 with fMLP induces a small population of neutrophils with slow transit. This experimental
337 approach provides a platform for probing the mechanisms by which neutrophils modulate their
338 deformability.

339

340 *Transit behavior of neutrophils derived from progenitor cell lines*

341 To further investigate the mechanisms of actin polymerization and remodeling and
342 regulation of neutrophil stiffness, we derived neutrophils from HoxB8-conditional progenitors.
343 This experimental system allows for the generation of knockout cell lines that can be maintained
344 in their progenitor state and subsequently differentiated into mature neutrophils. First, we used
345 our microfluidic platform and analyses to establish that neutrophils derived from HoxB8-
346 conditional progenitors transit through constrictions and respond to stimuli similarly to BMNs.

347 In experiments with BMNs, we observed that fewer than 5% of neutrophils exhibited
348 fMLP-induced activation features, such as the neutrophil transit with slow phase kinetics. In
349 subsequent experiments, we aimed to more deliberately expose cells to the stimulus within the
350 microfluidics prior to reaching the constriction channel. Microfluidic design B includes a long
351 mixing channel to ensure adequate exposure to the stimulus (Figure 1). In the supplemental data,
352 we show the distribution of fluorescein before and after the mixing channel (Figure S2),
353 indicating thorough mixing and a uniform exposure to stimulus in this device. Due to the
354 extremely small dimensions of the microfluidic device, the addition of this channel added
355 significant flow resistance to the experiment. We therefore used a syringe pump in experiments
356 employing microfluidic design B to overcome this resistance and instead set the flow rate to
357 match the fluid flow velocity to that of the capillaries in the lung, estimated between 109 $\mu\text{m/s}$ –

358 280 $\mu\text{m/s}$ [15, 36, 37]. We performed calibration assays with fluorescent beads and neutrophils to
359 confirm the flow velocity of 130 $\mu\text{m/s}$ through the constriction array for the systemic $1\mu\text{L/min}$
360 flow rate (Figure S3).

361 We perfused wild-type (WT) neutrophils differentiated from HoxB8-conditional
362 progenitors through the microfluidic platform and characterized their transit time distribution. In
363 analyses of the distribution of neutrophil transit times, a single exponential curve describes the
364 transit times of unstimulated neutrophils, while fMLP-stimulated neutrophils require two a two-
365 phase exponential rise (Figure 4A, 4B). Neutrophils treated with CytoD exhibited transit times
366 characterized by a single-phase exponential curve. In contrast to BMNs, these studies yielded
367 transit time distributions that did not exhibit a lag phase. This may be due to the change in
368 microfluidic design and implementation. The average transit time for control neutrophils and
369 neutrophils exposed to fMLP and CytoD are 1.0 s [95% CI 0.98 – 1.1] and 0.21 s [95% CI 0.17 –
370 0.26], respectively (Figure 4C). For neutrophils stimulated with fMLP, the average transit time
371 within the fast phase is 0.46 s [95% CI 0.41 – 0.52], while the slow phase had an average transit
372 time of 5.2 s [95% CI 4.5 – 6.1] (Figure 4C). Though the transit times are shorter than those for
373 BMNs as expected due to the increased flow rates, only 67% [95% CI 64 – 69] of the fMLP-
374 stimulated neutrophils populate the fast phase (Figure 4B).

375

376 *Vinculin regulates neutrophil deformability and transit through 5- μm constrictions*

377 Vinculin is an actin-binding protein whose role in cortical actin organization is well
378 understood in mesenchymal cells but less so in neutrophils [28, 29]. Using CRISPR/Cas9 to
379 generate $Vcl^{-/-}$ progenitors which were then differentiated into neutrophils, we investigated the
380 role of vinculin in neutrophil stiffening and transit through model capillaries.

381 We perfused WT and $Vcl^{-/-}$ neutrophils through the microfluidic platform and recorded
382 the transit times (Figure 5A). Analyses of transit time curves indicates that WT neutrophils
383 stimulated with fMLP were the only group that had a two-phase transit time distribution (Figure
384 5B), as described above. In contrast, $Vcl^{-/-}$ neutrophils stimulated with fMLP have a single phase
385 with an average transit time of 0.65 s [95% CI 0.60 – 0.70] (Figure 5C). Unstimulated $Vcl^{-/-}$
386 neutrophils have an average transit time of 0.57 s [95% CI 0.51 – 0.64] (Figure 5C). While the
387 average dwell time within the fast phase of fMLP-stimulated WT neutrophils is less than that of
388 $Vcl^{-/-}$ neutrophils, because all $Vcl^{-/-}$ neutrophil transit events exist within the fast phase regime

389 their overall transit is faster than that of WT neutrophils. Finally, we observed the shortest transit
390 times for $Vcl^{-/-}$ neutrophils pretreated with CytoD and stimulated with fMLP, with an average
391 dwell time of 0.12 s [95% CI 0.11 – 0.13] (Figure 5C). These data indicate that vinculin plays a
392 crucial role in inducing slow-transiting neutrophils in response to fMLP.

393 The development of resistance to changes in deformability prolong neutrophil transit in
394 the pulmonary microvasculature. To directly probe neutrophil deformability, we performed
395 analyses of neutrophils derived from HoxB8-conditional progenitors using atomic force
396 microscopy. In these experiments, neutrophils were allowed to settle on a glass coverslip and
397 remained in a rounded morphology, as indicated by a constant cell height across all experimental
398 conditions (Figure 6A). In the absence of stimulus, WT and $Vcl^{-/-}$ neutrophils had a similar
399 elastic modulus (Figure 6B). We found that $Vcl^{-/-}$ neutrophils have a lower elastic modulus than
400 WT neutrophils when stimulated with fMLP (Figure 6B). Together, these data indicate that the
401 faster transit properties of $Vcl^{-/-}$ neutrophils are likely due to an abrogated stiffening response to
402 activation-induced actin remodeling.

403

404 *Vinculin and neutrophil sequestration in the lungs*

405 To evaluate the impact of vinculin-dependent neutrophil stiffening on in the acute
406 accumulation of neutrophils in the lungs, we performed studies in an *in vivo* mouse model of
407 pulmonary neutrophil sequestration. Experiments utilized mixed chimeric mice that harbor both
408 WT and $Vcl^{-/-}$ neutrophils, distinguished by the co-expression of GFP [29]. We administered
409 granulocyte-macrophage cell-stimulating factor (GM-CSF) intravenously to induce neutrophil
410 priming, stiffening, and sequestration [42]. After evacuating the lungs of non-sequestered
411 neutrophils, we analyzed the remaining WT and $Vcl^{-/-}$ neutrophils and compared their relative
412 frequencies to those observed in the circulation (Figure 7). These data, expressed as the
413 frequency of $Vcl^{-/-}$ neutrophils relative to WT, indicate that GM-CSF induces the sequestration
414 of more WT neutrophils relative to $Vcl^{-/-}$ neutrophils in the lungs, as compared to their ratio in
415 the blood (Figure 7). These data demonstrate that vinculin plays a role in the acute GM-CSF-
416 induced sequestration of neutrophils in the lung, and are consistent with the phenotype of
417 vinculin-deficient neutrophils lacking a defined population with slow phase transit kinetics in
418 microfluidic analyses.

419

420 *Vinculin is not essential for neutrophil phagocytosis*

421 Our results indicate that vinculin has a role in the actin-dependent modulation of
422 neutrophil stiffening and transit through narrow constrictions. Given the important role of actin
423 reorganization in other neutrophil functions, we investigated the potential role of vinculin in
424 neutrophil phagocytosis. Phagocytosis is a specialized F-actin-dependent form of endocytosis
425 that is critical for the antimicrobial function of many immune cells, including monocytes,
426 macrophages, neutrophils, dendritic cells, osteoclasts, and eosinophils [43]. To determine
427 whether vinculin plays a role in neutrophil phagocytosis, we performed experiments to evaluate
428 the uptake of non-viable *Staphylococcus aureus*. We incubated neutrophils with pHrodo-
429 conjugated *S. aureus* bioparticles and assayed their uptake after 90 min. We found that *Vcl*^{-/-}
430 neutrophils phagocytosed the microbe just as well as WT neutrophils (Figure 8). As expected,
431 disruption of the actin cytoskeleton with CytoD abrogated phagocytosis (Figure 8). Thus, while
432 neutrophil stiffening in response to fMLP is inhibited by the loss of vinculin, actin-dependent
433 phagocytosis is maintained.

434

435

436 **Discussion**

437 The extensive microvasculature of the lungs provides the massive surface area necessary
438 for blood-gas exchange to oxygenate tissues throughout the body. The circulation is also the
439 highway by which immune cells survey and traffic to tissue sites. Neutrophils, as the most
440 abundant leukocyte in the circulation, frequently pass through the pulmonary capillary network
441 and must deform to do so. As we observe in our microfluidic model of capillary segments, the
442 process of neutrophil passage slows their transit relative to the bulk flow, a phenomenon that
443 results in the enrichment of neutrophils within the pulmonary capillaries relative to other
444 vascular beds, even at homeostasis when neutrophils are uniformly in a basal, inactive state [10].
445 Under conditions in which neutrophils receive activating signals, either from local inflammation
446 of the lung or a systemic inflammatory response, neutrophils accumulate in the pulmonary
447 capillaries [10, 23]. It was subsequently established that physical trapping of neutrophils in the
448 lung capillaries is an actin-dependent process and leads to their retention [10, 23]. Specifically,
449 physical trapping due to cortical actin assembly-induced neutrophil stiffening mediates initial
450 sequestration, whereas $\beta 2$ integrins play a role in prolonging neutrophil retention [26]. While
451 these broader mechanisms have been known for almost 30 years, the specific intracellular
452 mediators of actin reorganization that drive neutrophil stiffening still remain unclear.

453 Our studies aimed to take advantage of microfluidics to precisely design features at scale
454 and thereby establish a tractable experimental system to probe the mechanisms of neutrophil
455 transit in model pulmonary capillary units. Constriction microfluidics enables quantification of
456 the functional elastic modulus, or stiffness, of the whole body of the cell by applying the pressure
457 of fluid perfusion to force it to deform in order to passage through a narrow channel. An
458 advantage of the design flexibility of microfluidics is that by using a separate inlet for the
459 stimulus, one can control the timing for exposure of neutrophils to a stimulus and ensure that
460 each cell experiences the chemical for a similar amount of time prior to encountering the
461 constriction channel. Thus, these experiments allow a neutrophil to respond to both a
462 biochemical signal and mechanical deformation via the microfluidic device. This model, which
463 mimics the pulmonary capillary system, is not achievable with the classical methods of testing
464 mechanical properties such as AFM and cell aspiration [44]. Additionally, this approach allows
465 for the examination of many more events than what is feasible with other techniques. The
466 microfluidic mid-throughput assay allows us to collect single-cell mechanical data on hundreds

467 to thousands of cells, yielding robust data collection that then provides access to more
468 sophisticated data analysis techniques in which one can analyze population-based effects.

469 In our study, the number of neutrophil transit events analyzed in each data set allowed us
470 to confidently fit the data to continuous functions. By taking advantage of data analysis
471 techniques optimized with single-particle tracking, we fit the cumulative distribution curves of
472 transit times to exponential rise functions. Under certain experimental conditions, it was
473 necessary to employ more than one exponential rise to accurately fit the data, suggesting that
474 distinct populations of neutrophils give rise to that particular trend. This is illustrated by the need
475 for at least a 2-phase exponential function to fit the data for BMN transit in the presence of fMLP
476 stimulus. Analyses of BMN transit time indicated that the addition of fMLP results in a subset of
477 neutrophils undergoing stiffening that acted to increase their transit time 28-fold compared to
478 neutrophils that did not respond. It is possible that there may be additional biologically distinct
479 populations than we resolve using this approach, but many more neutrophil transit events would
480 need to be analyzed to gain the statistical power to distinguish them.

481 In our analyses of BMNs, the transit time curves of both the control and fMLP-stimulated
482 group have a lag phase. By determining the x-intercept of the two lag phases of the control and
483 stimulus and the x-intercept of the exponential rise of the negative control, we observe that a
484 little less than a second is the fastest any cell can transit under these conditions. In addition, the
485 lag phase of the stimulus and control groups indicates that the basal neutrophil stiffness results in
486 a shift that increases the minimum transit time compared to the negative control group that was
487 exposed to CytoD to disrupt the actin cytoskeleton. In other words, the basal tone of neutrophils
488 results in a bottleneck that makes it rare to observe a cell transit faster than 1.5 s, which is in
489 contrast to neutrophils treated with CytoD in which over 30% of the neutrophils have transited in
490 less than 1.5 s.

491 Similar to the neutrophil transit subpopulation dynamics observed in studies with BMNs,
492 analyses of neutrophils derived from HoxB8-conditional progenitors revealed the fMLP-induced
493 appearance of a stiffened neutrophil subset whose transit times were characterized by a second
494 exponential phase of the curve fit. By introducing a stimulus-mixing channel into the
495 microfluidic platform, we found an increased proportion of neutrophils in the subset described by
496 slow phase transit kinetics in response to fMLP. It is intriguing that despite uniform exposure to
497 the stimulus, only a fraction of neutrophils exhibit slower transit kinetics. This was not a feature

498 unique to the microfluidic system, as AFM analyses also suggested that only a proportion of
499 neutrophils shift towards a drastically increased elastic modulus in response to fMLP. Together,
500 these findings indicate the flexibility and robustness of using microfluidics to probe neutrophil
501 passage through narrow channels, and also establish that neutrophils derived from HoxB8-
502 conditional progenitors modulate their deformability in response to stimuli in a similar manner as
503 primary neutrophils.

504 In previous studies, our lab established that vinculin plays a role in neutrophil adhesion
505 and motility that depends upon the experimental context (e.g., presence of fluid flow) [29].
506 While those studies probed integrin-dependent neutrophil motility on two-dimensional surfaces,
507 here we focused on the potential role of vinculin in aspects of neutrophil trafficking that occur
508 while a neutrophil is still in a round morphology, as does while circulating. We found that
509 vinculin deficiency abrogated the neutrophil stiffening response to fMLP, manifested by $Vcl^{-/-}$
510 neutrophils not developing a second population with slow phase transit kinetics in response to
511 fMLP. Instead, the average transit time of fMLP-stimulated $Vcl^{-/-}$ neutrophils (0.6 s) was similar
512 to that of unstimulated WT (1.0 s) and of unstimulated $Vcl^{-/-}$ neutrophils (0.6 s), differences that
513 are not likely to be biologically meaningful. Interestingly, vinculin-deficient neutrophils whose
514 actin cytoskeleton was disrupted with CytoD exhibited the shortest average transit times of all
515 conditions evaluated. This suggests that $Vcl^{-/-}$ neutrophils retain some basal level of actin-
516 dependent stiffness that may be organized in structures that do not involve vinculin.

517 Neutrophil stiffening and sequestration in pulmonary capillaries represents a
518 physiological mechanism for host defense of the lungs [10]. However, under pathophysiologic
519 conditions such as those present in ARDS, continued accumulation of neutrophils in the
520 pulmonary capillary bed and their premature deployment of antimicrobial defenses contributes to
521 injury of host tissues [5, 9]. Here, we demonstrate that vinculin plays a role in neutrophil
522 sequestration *in vivo* in response to GM-CSF, an agent that rapidly primes neutrophils and
523 induces their transient retention in the lung [42]. Understanding the mechanisms of
524 pathophysiological neutrophil sequestration in the lungs, and whether they are distinct from
525 those that we identify in this study, should be the subject of future investigation. We observed
526 that $Vcl^{-/-}$ neutrophils are able to engulf and internalize *S. aureus*, indicating that the actin-
527 dependent process of phagocytosis that is key for intracellular eradication of microbes does not

528 require vinculin. This suggests the feasibility of therapeutically targeting neutrophil stiffening
529 while sparing important host defense functions of neutrophils.

530

531 **Acknowledgments:** We thank Dr. Paul Ekert, Dr. Patrice Dubreuil, and Dr. Amy Rowat for
532 kindly providing reagents, resources, or advice to conduct the studies.

533

534 **Funding:** This research was supported by awards from the National Institutes of Health:
535 R35GM124911 to C.T.L.; T32HL134625 supported B.M.N., R25HL088992 supported Y.R. and
536 K.A..

537

538 **Author Contributions:**

539 B.M.N.: Conceiving and designing experiments, conducting experiments, analyzing data, writing
540 and editing the manuscript.

541 Z.S.W.: Conceiving and designing experiments, conducting experiments, analyzing data.

542 K.A.: Conducting experiments.

543 Y.R.: Conducting experiments.

544 M.K.S.: Helping to conduct and analyze AFM experiments.

545 E.M.D.: Supervising AFM experiments.

546 C.T.L.: Supervising the project, conceiving and designing experiments, writing and editing the
547 manuscript.

548

549 **Competing Interests:**

550 The authors have declared that no competing interests exist.

551 References

- 552 1. Eworuke, E., Major, J. M., McClain, L. I. G. National incidence rates for Acute Respiratory
553 Distress Syndrome (ARDS) and ARDS cause-specific factors in the United States (2006-
554 2014). *Journal of Critical Care*. 2018;47, 192-197.
- 555 2. Bellani, G., Laffey, J. G., Pham, T., et al. Epidemiology, Patterns of Care, and Mortality
556 for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50
557 Countries. *Jama-Journal of the American Medical Association*. 2016;315, 788-800.
- 558 3. Biehl, M., Ahmed, A., Kashyap, R., et al. The Incremental Burden of Acute Respiratory
559 Distress Syndrome: Long-term Follow-up of a Population-Based Nested Case-Control
560 Study. *Mayo Clin Proc*. 2018;93, 445-452.
- 561 4. Alipanah, N. and Calfee, C. S. Phenotyping in acute respiratory distress syndrome: state of
562 the art and clinical implications. *Current Opinion in Critical Care*. 2022;28, 1-8.
- 563 5. Yang, S. C., Tsai, Y. F., Pan, Y. L., et al. Understanding the role of neutrophils in acute
564 respiratory distress syndrome. *Biomedical Journal*. 2021;44, 439-446.
- 565 6. Aulakh, G. K. Neutrophils in the lung: "the first responders". *Cell Tissue Res*. 2018;371,
566 577-588.
- 567 7. Palakshappa, J. A., Krall, J. T. W., Belfield, L. T., et al. Long-Term Outcomes in Acute
568 Respiratory Distress Syndrome Epidemiology, Mechanisms, and Patient Evaluation.
569 *Critical Care Clinics*. 2021;37, 895-911.
- 570 8. Chiumello, D., Coppola, S., Froio, S., et al. What's Next After ARDS: Long-Term
571 Outcomes. *Respiratory Care*. 2016;61, 689.
- 572 9. Grommes, J. and Soehnlein, O. Contribution of neutrophils to acute lung injury. *Mol Med*.
573 2011;17, 293-307.
- 574 10. Doerschuk, C. M. Mechanisms of leukocyte sequestration in inflamed lungs.
575 *Microcirculation*. 2001;8, 71-88.
- 576 11. Doerschuk, C. M. Neutrophil rheology and transit through capillaries and sinusoids. *Am J*
577 *Respir Crit Care Med*. 1999;159, 1693-5.
- 578 12. Reutershan, J. and Ley, K. Bench-to-bedside review: Acute respiratory distress syndrome
579 how neutrophils migrate into the lung. *Critical Care*. 2004;8, 453-461.
- 580 13. Shirai, A. Modeling neutrophil transport in pulmonary capillaries. *Respiratory Physiology*
581 *& Neurobiology*. 2008;163, 158-165.
- 582 14. Ekpenyong, A. E., Toepfner, N., Fiddler, C., et al. Mechanical deformation induces
583 depolarization of neutrophils. *Sci Adv*. 2017;3, e1602536.
- 584 15. Ekpenyong, A. E., Toepfner, N., Chilvers, E. R., et al. Mechanotransduction in neutrophil
585 activation and deactivation. *Biochim Biophys Acta*. 2015;1853, 3105-16.
- 586 16. Looney, M. R. and Bhattacharya, J. (2014) Live Imaging of the Lung. In Annual Review
587 of Physiology, Vol 76, Volume 76 (D. Julius, ed) 431-445.
- 588 17. Mizgerd, J. P., Meek, B. B., Kutkoski, G. J., et al. Selectins and neutrophil traffic:
589 Margination and Streptococcus pneumoniae-induced emigration in murine lungs. *Journal*
590 *of Experimental Medicine*. 1996;184, 639-645.
- 591 18. Bullard, D. C., Kunkel, E. J., Kubo, H., et al. Infections and deficiency of leukocyte rolling
592 and recruitment in E-/P-selectin mutant mice. *Faseb Journal*. 1996;10, 1605-1605.
- 593 19. Doerschuk, C. M., Winn, R. K., Coxson, H. O., et al. CD18-DEPENDENT AND CD18-
594 INDEPENDENT MECHANISMS OF NEUTROPHIL EMIGRATION IN THE

- 595 PULMONARY AND SYSTEMIC MICROCIRCULATION OF RABBITS. *Journal of*
596 *Immunology*. 1990;144, 2327-2333.
- 597 20. Diz-Munoz, A., Fletcher, D. A., Weiner, O. D. Use the force: membrane tension as an
598 organizer of cell shape and motility. *Trends Cell Biol*. 2013;23, 47-53.
- 599 21. Marucha, P., Mercado, A., Fernandez, M. REGULATION OF ACTIN EXPRESSION IN
600 GM-CSF-INDUCED PMN. *Journal of Dental Research*. 1995;74, 130-130.
- 601 22. Bochsler, P. N., Neilsen, N. R., Dean, D. F., et al. STIMULUS-DEPENDENT ACTIN
602 POLYMERIZATION IN BOVINE NEUTROPHILS. *Inflammation*. 1992;16, 383-392.
- 603 23. Worthen, G. S., Schwab, B., Elson, E. L., et al. MECHANICS OF STIMULATED
604 NEUTROPHILS - CELL STIFFENING INDUCES RETENTION IN CAPILLARIES.
605 *Science*. 1989;245, 183-186.
- 606 24. Gebb, S. A., Graham, J. A., Hanger, C. C., et al. SITES OF LEUKOCYTE
607 SEQUESTRATION IN THE PULMONARY MICROCIRCULATION. *Journal of*
608 *Applied Physiology*. 1995;79, 493-497.
- 609 25. Andonegui, G., Bonder, C. S., Green, F., et al. Endothelium-derived Toll-like receptor-4 is
610 the key molecule in LPS-induced neutrophil sequestration into lungs. *J Clin Invest*.
611 2003;111, 1011-20.
- 612 26. Doerschuk, C. M. THE ROLE OF CD18-MEDIATED ADHESION IN NEUTROPHIL
613 SEQUESTRATION INDUCED BY INFUSION OF ACTIVATED PLASMA IN
614 RABBITS. *American Journal of Respiratory Cell and Molecular Biology*. 1992;7, 140-
615 148.
- 616 27. Peng, X., Nelson, E. S., Maiers, J. L., et al. New insights into vinculin function and
617 regulation. *Int Rev Cell Mol Biol*. 2011;287, 191-231.
- 618 28. Cohen, J. T., Danise, M., Hinman, K. D., et al. Engraftment, Fate, and Function of HoxB8-
619 Conditional Neutrophil Progenitors in the Unconditioned Murine Host. *Frontiers in Cell*
620 *and Developmental Biology*. 2022;10.
- 621 29. Wilson, Z. S., Witt, H., Hazlett, L., et al. Context-Dependent Role of Vinculin in
622 Neutrophil Adhesion, Motility and Trafficking. *Sci Rep*. 2020;10, 2142.
- 623 30. Wang, G. G., Calvo, K. R., Pasillas, M. P., et al. Quantitative production of macrophages
624 or neutrophils ex vivo using conditional Hoxb8. *Nature Methods*. 2006;3, 287-293.
- 625 31. Kanthilal, M. and Darling, E. M. Characterization of mechanical and regenerative
626 properties of human, adipose stromal cells. *Cell Mol Bioeng*. 2014;7, 585-597.
- 627 32. Darling, E. M., Zauscher, S., Block, J. A., et al. A thin-layer model for viscoelastic, stress-
628 relaxation testing of cells using atomic force microscopy: do cell properties reflect
629 metastatic potential? *Biophys J*. 2007;92, 1784-91.
- 630 33. Dimitriadis, E. K., Horkay, F., Maresca, J., et al. Determination of elastic moduli of thin
631 layers of soft material using the atomic force microscope. *Biophys J*. 2002;82, 2798-810.
- 632 34. Zemljic-Harpf, A. E., Miller, J. C., Henderson, S. A., et al. Cardiac-myocyte-specific
633 excision of the vinculin gene disrupts cellular junctions, causing sudden death or dilated
634 cardiomyopathy. *Mol Cell Biol*. 2007;27, 7522-37.
- 635 35. Velasco-Hernandez, T., Säwén, P., Bryder, D., et al. Potential Pitfalls of the Mx1-Cre
636 System: Implications for Experimental Modeling of Normal and Malignant Hematopoiesis.
637 *Stem cell reports*. 2016;7, 11-18.
- 638 36. Wagner, W. W., Latham, L. P., Gillespie, M. N., et al. DIRECT MEASUREMENT OF
639 PULMONARY CAPILLARY TRANSIT TIMES. *Science*. 1982;218, 379-381.

- 640 37. Eichhorn, M. E., Ney, L., Massberg, S., et al. Platelet kinetics in the pulmonary
641 microcirculation in vivo assessed by intravital microscopy. *Journal of Vascular Research*.
642 2002;39, 330-339.
- 643 38. Tinevez, J.-Y., Perry, N., Schindelin, J., et al. TrackMate: An open and extensible platform
644 for single-particle tracking. *Methods*. 2017;115, 80-90.
- 645 39. Schindelin, J., Arganda-Carreras, I., Frise, E., et al. Fiji: an open-source platform for
646 biological-image analysis. *Nature Methods*. 2012;9, 676-682.
- 647 40. Nguyen, A. V., Nyberg, K. D., Scott, M. B., et al. Stiffness of pancreatic cancer cells is
648 associated with increased invasive potential. *Integr Biol (Camb)*. 2016;8, 1232-1245.
- 649 41. Hoelzle, D. J., Varghese, B. A., Chan, C. K., et al. A Microfluidic Technique to Probe Cell
650 Deformability. *Jove-Journal of Visualized Experiments*. 2014.
- 651 42. Summers, C., Singh, N. R., White, J. F., et al. Pulmonary retention of primed neutrophils:
652 a novel protective host response, which is impaired in the acute respiratory distress
653 syndrome. *Thorax*. 2014;69, 623-629.
- 654 43. Rosales, C. and Uribe-Querol, E. Phagocytosis: A Fundamental Process in Immunity.
655 *BioMed research international*. 2017;2017, 9042851-9042851.
- 656 44. Ren, C. G., Yuan, Q. Y., Braun, M., et al. Leukocyte Cytoskeleton Polarization Is Initiated
657 by Plasma Membrane Curvature from Cell Attachment. *Developmental Cell*. 2019;49, 206-
658 +.
- 659
- 660

661 **Figure legends**

662 **Figure 1. Schematics of microfluidic device designs.** (A) Design and layout of the microfluidic
663 device used in the bone marrow neutrophil experiments. The driving pressure was 10 cmH₂O.
664 (B) Microfluidic design used for studies using HoxB8-conditional progenitor-derived
665 neutrophils. In this design a mixing channel is included to ensure uniform stimulus exposure. A
666 syringe pump set to 500 nl/min was used to perfuse the device at a constant flow rate.

667
668 **Figure 2. Neutrophil transit data analysis workflow.** (A) An example time series of a
669 neutrophil transiting a constriction. (B) The data analysis workflow that yields transit time for
670 each neutrophil passage event that can be exported to Prism for fitting. (C) An example cell
671 position plot from the TrackMate plugin that shows cell identification (highlighted with a purple
672 circle) and the linked tracks for quantifying cell transit over time.

673
674 **Figure 3. Bone marrow neutrophil transit time distributions and impact of fMLP.** (A)
675 Cumulative distributions of BMN transit times for control (blue), stimulated with fMLP (red),
676 and treated with CytoD and fMLP (black). The control group was fit with a linear trend (inset,
677 light blue) and a single-phase exponential rise (dark blue). The fMLP-stimulated group was fit
678 with a linear trend (inset, light red) and a 2-phase exponential rise (dark red). The BMN group
679 treated with CytoD and fMLP was fit with a single-phase exponential rise. (B) The best fit values
680 of the average transit times determined from the fits in (A). The lag phase is associated with the
681 linear fit, the fast phase of the control and CytoD/fMLP data sets is associated with a single
682 exponential rise, and the fast and slow phases for the fMLP-stimulated group data set is
683 associated with a 2-phase exponential rise. (C) The best fit values of the magnitude of the fast
684 phase population determined from the 2-phase exponential rise fits in (A) for the data set of
685 fMLP-stimulated BMNs. Since the control and the CytoD/fMLP data sets fit to a single
686 exponential rise, their population was entered as 100% for clarity. (D) The population
687 distribution of each group, recalculated to include the lag phase proportion of the control and
688 fMLP-stimulated group data sets.

689

690 **Figure 4. Transit time distributions of wild-type (WT) neutrophils derived from HoxB8-**
691 **conditional progenitors.** (A) The cumulative distributions of transit times for WT control
692 (blue), WT stimulated with fMLP (red), and WT treated with CytoD and fMLP (black). The WT
693 control group was fit with a single-phase exponential rise. The fMLP-stimulated group was fit
694 with a 2-phase exponential rise. The CytoD/fMLP group was fit with a single-phase exponential
695 rise. (B) The best fit values of the average transit times determined from the fits in (A). (C) The
696 population distributions of WT neutrophils under each condition, determined from the best fit
697 values in (A).

698

699 **Figure 5. Transit time distributions of WT and $Vcl^{-/-}$ neutrophils.** (A) The cumulative
700 distributions of transit times for WT stimulated with fMLP (red), $Vcl^{-/-}$ stimulated with fMLP
701 (green), $Vcl^{-/-}$ control (aqua), and $Vcl^{-/-}$ treated with CytoD and fMLP (purple). The group of WT
702 neutrophils treated with fMLP was fit with a 2- phase exponential rise. All other data sets in this
703 figure were fully described by a single-phase exponential rise. (B) Comparison among groups of
704 the best fit values of the average transit times determined from the fits in (A).

705

706 **Figure 6. AFM analyses of WT and $Vcl^{-/-}$ neutrophils.** Neutrophils were allowed to settle on
707 coverslips and then exposed to control conditions or 1 μ M fMLP. (A) The cell height and (B)
708 elastic modulus (Pa) for each cell was measured by AFM as described in the Methods.
709 Measurements from each cell are single data points on the plots shown. $n > 56$ cells per group.
710 Data were analyzed using two-way ANOVA with Tukey multiple comparisons test. **** $p <$
711 0.001.

712

713 **Figure 7. GM-CSF-induced neutrophil sequestration in the lungs of mixed chimeric mice.**
714 Mice harboring both WT and $Vcl^{-/-}$ neutrophils received intravenous injection of GM-CSF. After
715 15 min, mice were euthanized and the blood and lungs harvested for analyses. Data are
716 expressed as the percentage of $Vcl^{-/-}$ neutrophils in the blood and lung. $n = 5$ mice across two
717 independent experiments. Data were analyzed using a paired Student's t-test. * $p < 0.05$.

718

719 **Figure 8. Neutrophil phagocytosis of *S. aureus* bioparticles.** WT and *Vcl*^{-/-} neutrophils derived
720 from HoxB8-conditional progenitors were incubated with pHrodo Green-conjugated *S. aureus*
721 bioparticles for 90 min at 37°C and analyzed by flow cytometry to quantify the percentage of
722 viable neutrophils that successfully internalized *S. aureus*. To demonstrate the dependence of
723 phagocytosis on the actin cytoskeleton, a group of samples were incubated with 10 µg/mL
724 CytoD. For the 0 min time point, the reaction is immediately quenched after addition of *S.*
725 *aureus*.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8

